[1] Liu J, Zhang SK, Wang QM, Shen HP, Zhang M, Zhang YP, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016;16(1):80 − 6. http://dx.doi.org/10.1016/S1473-3099(15)00218-2CrossRef
[2] Zeng N, Zou CL, He ZY, Ma H, Ou XJ, You H, et al. Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. Int J Infect Dis 2018;67:58 − 64. http://dx.doi.org/10.1016/j.ijid.2017.11.011CrossRef
[3] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. The Guidelines of prevention and treatment for chronic hepatitis B (2019 Version). Chin J Hepatol 2019;27(12):938 − 61. http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2019.12.007 (In Chinese)CrossRef
[4] Hou JL, Wang GQ, Wang FS, Cheng J, Ren H, Zhunag H, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol 2017;5(4):297 − 318. http://dx.doi.org/10.14218/JCTH.2016.00019CrossRef
[5] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007;120(24): 2159-73. https://pubmed.ncbi.nlm.nih.gov/18167196/.https://pubmed.ncbi.nlm.nih.gov/18167196/
[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol 2011;19(1):13 − 24. http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2011.01.007 (In Chinese)CrossRef
[7] Huang JX, Guan ML, Balch J, Wu E, Rao HY, Lin A, et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int 2016;36(11):1595 − 603. http://dx.doi.org/10.1111/liv.13168CrossRef
[8] Li M, Kong YY, Wu SS, Zhou JL, Wu XN, Wang L, et al. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. J Dig Dis 2019;20(9):467 − 75. http://dx.doi.org/10.1111/1751-2980.12794CrossRef
[9] Chan HLY, Wong VWS, Tse AML, Tse CH, Chim AML, Chan HY, et al. Serum Hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5(12):1462 − 8. http://dx.doi.org/10.1016/j.cgh.2007.09.005CrossRef
[10] Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 2013;62(1):182 − 4. http://dx.doi.org/10.1136/gutjnl-2012-302656CrossRef
[11] Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014;93(29):e322. http://dx.doi.org/10.1097/MD.0000000000000322CrossRef
[12] Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect 2015;21(2):197 − 203. http://dx.doi.org/10.1016/j.cmi.2014.10.002CrossRef
[13] Fan R, Sun J, Yuan Q, Xie Q, Bai XF, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut 2016;65(2):313 − 20. http://dx.doi.org/10.1136/gutjnl-2014-308546CrossRef
[14] Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 2015;5(3):218 − 26. http://dx.doi.org/10.7150/thno.10636CrossRef
[15] Chi H, Li ZD, Hansen BE, Yu T, Zhang XY, Sun J, et al. Serum level of antibodies against Hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol 2019;17(1):182 − 91.e1. http://dx.doi.org/10.1016/j.cgh.2018.05.047CrossRef
[16] Wang J, Shen T, Huang XB, Kumar GR, Chen XM, Zeng ZZ, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65(4):700 − 10. http://dx.doi.org/10.1016/j.jhep.2016.05.029CrossRef
[17] Fan R, Zhou B, Xu M, Tan DM, Niu JQ, Wang H, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol 2020;18(3):719 − 27.e7. http://dx.doi.org/10.1016/j.cgh.2019.07.046CrossRef
[18] Jia JD, Hou JL, Ding HG, Chen GF, Xie Q, Wang YM, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30(4):756 − 62. http://dx.doi.org/10.1111/jgh.12840CrossRef
[19] Xu YM, Liu YH, Cao ZJ, Wang L, Li ZQ, et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: single-center prospective study. Dig Liver Dis 2019;51(9):1323 − 9. http://dx.doi.org/10.1016/j.dld.2019.02.009CrossRef
[20] Xu SY, Wang Y, Tai DCS, Wang S, Cheng CL, Peng QW, et al. qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol 2014;61(2):260 − 9. http://dx.doi.org/10.1016/j.jhep.2014.02.015CrossRef
[21] Sun YM, Zhou JL, Wang L, Wu XN, Chen YP, Piao HX, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology 2017;65(5):1438 − 50. http://dx.doi.org/10.1002/hep.29009CrossRef
[22] Sun YM, Wu XN, Zhou JL, Meng TT, Wang BQ, Chen SY, et al. Persistent low level of Hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol 2020. http://dx.doi.org/10.1016/j.cgh.2020.03.001CrossRef
[23] Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol 2020;18(2):457 − 67.e21. http://dx.doi.org/10.1016/j.cgh.2019.07.010CrossRef
[24] Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol 2015;21(25):7869 − 76. http://dx.doi.org/10.3748/wjg.v21.i25.7869CrossRef
[25] Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36(12):1755 − 64. http://dx.doi.org/10.1111/liv.13253CrossRef
[26] Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat 2015;22(2):85 − 93. http://dx.doi.org/10.1111/jvh.12313CrossRef
[27] Liang XE, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int 2019;13(3):260 − 9. http://dx.doi.org/10.1007/s12072-019-09943-6CrossRef
[28] Wu XN, Zhou JL, Xie W, Ding HG, Ou XJ, Chen GF, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist 2019;12:745 − 57. http://dx.doi.org/10.2147/IDR.S185120CrossRef
[29] Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, et al. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20(11):811 − 20. http://dx.doi.org/10.1111/jvh.12115CrossRef
[30] Jia JT, Tang H, Ning Q, Jiang JJ, Dou XG, Zhang MX, et al. Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results. Antivir Ther 2018;23(3):201 − 9. http://dx.doi.org/10.3851/imp3205CrossRef
[31] Zhang W, Wang XM, Wang Y, Zhao XY, Duan WJ, Wang QY, et al. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: results of a 10-year follow up. Medicine (Baltimore) 2017;96(44):e8454. http://dx.doi.org/10.1097/MD.0000000000008454CrossRef
[32] Li M, Lv TT, Wu SS, Wei W, Wu XH, Ou XJ, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14(1):105 − 14. http://dx.doi.org/10.1007/s12072-019-10005-0CrossRef
[33] Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat 2019;26(10):1146 − 55. http://dx.doi.org/10.1111/jvh.13126CrossRef
[34] Ning Q, Han MF, Sun YT, Jiang JJ, Tan DM, Hou JL, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61(4):777 − 84. http://dx.doi.org/10.1016/j.jhep.2014.05.044CrossRef
[35] Han MF, Jiang JJ, Hou JL, Tan DM, Sun YT, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study. Antivir Ther 2016;21(4):337 − 44. http://dx.doi.org/10.3851/IMP3019CrossRef
[36] Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol 2018;6(1):25 − 34. http://dx.doi.org/10.14218/JCTH.2017.00072CrossRef
[37] Wu D, Wang P, Han MF, Chen YP, Chen XY, Xia Q, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the endeavor study. Hepatol Int 2019;13(5):573 − 86. http://dx.doi.org/10.1007/s12072-019-09956-1CrossRef
[38] Gao ZL, Zhu X, Lin BL, Yi JH, GAo WJ, Chen YM, et al. The optimizing treatment of peg interferon Alfa in HbeAg negative chronic hepatitis B patients with low level HBsAg: a multicenter real world study (Interferon Cure Study, I CURE Study). Hepatology 2018;68(S1): 246A. https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30257.https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30257
[39] Xie Q, Cai W, Ouyang LJ, Gao YQ, Li SB, Xu J, et al. Effectiveness of response-guided peginterferon Alfa-2a therapy in nucleos(t)ide analogues treated patients with HBeAg-positive chronic hepatitis B: interim analysis of a prospective, multicenter, randomized study. Hepatology 2018;68(S1): 232A. https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30257.https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30257
[40] Cao ZH, Liu YL, Ma LN, Lu JF, Jin Y, Ren S, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology 2017;66(4):1058 − 66. http://dx.doi.org/10.1002/hep.29213CrossRef
[41] Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012;12(4):341 − 53. http://dx.doi.org/10.1016/S1473-3099(11)70314-0CrossRef
[42] Shan S, You H, Niu JQ, Shang J, Xie W, Zhang YX, et al. Baseline characteristics and treatment patterns of the patients recruited to the China registry of Hepatitis B. J Clin Transl Hepatol 2019;7(4):322 − 8. http://dx.doi.org/10.14218/JCTH.2019.00052CrossRef
[43] Kong YY, Wei W, Shan S, Ma H, Ou XJ, Xu XY, et al. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis. Chin Hepatol 2020;25(2):123 − 7. http://dx.doi.org/10.3969/j.issn.1008-1704.2020.02.012 (In Chinese)CrossRef
[44] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546 − 55. http://dx.doi.org/10.1016/S0140-6736(15)61412-XCrossRef
[45] The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3(6):383 − 403. http://dx.doi.org/10.1016/S2468-1253(18)30056-6CrossRef
[46] Nayagam S, Chan P, Zhao K, Sicuri E, Wang XC, Jia JD, et al. Investment case for a comprehensive package of interventions against Hepatitis B in China: applied modeling to help national strategy planning. Infect Dis 2020. http://dx.doi.org/10.1093/cid/ciaa134CrossRef
[47] Zu J, Li ML, Zhuang GH, Liang PF, Cui FQ, et al. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. Medicine (Baltimore) 2018;97(16):e0484. http://dx.doi.org/10.1097/MD.0000000000010484CrossRef